sevelamer

(redirected from Renvela)
Also found in: Dictionary.

sevelamer

 [sĕ-vel´ah-mer]
a phosphate binder used as the hydrochloride salt to reduce serum phosphorus concentrations in hyperphosphatemia associated with end-stage renal disease; administered orally.

sevelamer

/se·vel·a·mer/ (sĕ-vel´ah-mer) a phosphate-binding substance used as the hydrochloride salt to reduce serum phosphorus concentrations in hyperphosphatemia associated with end-stage renal disease.

sevelamer

[sĕvel′ahmer]
a phosphate binder used as the hydrochloride salt to reduce serum phosphorus concentrations in hyperphosphatemia associated with end-stage renal disease. It is administered orally.

sevelamer

A phosphate chelator used to reduce phosphorus in patients with end-stage renal disease and in chronic renal failure patients not requiring dialysis. It also reduces uric acid levels, and may be of use in patients with hyperuricaemia, uric acid nephrolithiasis and gout.

Adverse effects
Blood pressure lability (hypo- or hypertension), nausea, vomiting, dyspepsia, diarrhoea, constipation.

sevelamer

Renagel® Nephrology A chelator used to ↓ phosphorus in Pts with ESRD and in chronic renal failure Pts not requiring dialysis. See Chelation, End-stage renal disease.
References in periodicals archive ?
sales of Renvela and its generic equivalents totaled $1.
Renvela tablets had US sales of approximately USD1.
Healing could be delayed because changing the Renvela could affect that.
Renvela is a next generation version of Renagel, a calcium-free metal free, non-absorbed phosphate binder, and has the added benefit of a carbonate filter.
Renvela is being developed as a next generation phosphate binder to replace Renagel (sevelamer hydrochloride), the most-prescribed phosphate binder in the United States.
Pharmaceutical company Impax Laboratories Inc (NASDAQ:IPXL) reported on Monday the receipt of the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for the generic version of Renvela (sevelamer carbonate) tablets, 800 mg.
Genzyme says Renvela is a next generation version of Renagel, a calcium-free, metal-free, non-absorbed phosphate binder, and has the added benefit of a carbonate buffer.
M2 EQUITYBITES-October 24, 2017-US FDA approves Abbreviated New Drug Application for Impax Laboratories' Renvela tablets, 800mg
M2 PHARMA-October 24, 2017-US FDA approves Abbreviated New Drug Application for Impax Laboratories' Renvela tablets, 800mg
Cambridge, MA, announced it has launched its phosphate binder Renvela (sevelamer carbonate) for US dialysis patients, and says it has made significant progress in international efforts to secure additional approvals for the product.
Genzyme Corporation, Cambridge, MA, announced the FDA has granted marketing approval for Renvela for the control of serum phosphorus in patients with chronic kidney disease on dialysis.